Cerebrolysin
Cerebrolysin scored 5.2 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Pharmaceutical / Drug → Other Pharmaceutical.
Cerebrolysin is a porcine brain-derived peptide mixture given by IV or IM infusion. It has the largest human trial base of any nootropic-adjacent peptide, yet the maker-funded positive trials clash with two null-to-negative independent Cochrane reviews, per Ziganshina 2023, which is why it lands Neutral at 5.2.
What is Cerebrolysin?
Cerebrolysin is a porcine brain-derived peptide preparation, a mixture of small peptides and free amino acids extracted from pig brain tissue, given by intravenous infusion or intramuscular injection and marketed as neurotrophic, meaning it is meant to act like your body's own nerve growth factors. It is not a single defined molecule, which is unusual for something people inject. It is a biological extract whose batch composition is characterized in the lab but never reduced to one declared active ingredient, per Ziganshina et al. 2023. I am scoring Cerebrolysin as Neutral because it is genuinely interesting and genuinely unresolved at the same time, and pretending otherwise would not help you.
Here is why the score lands in the middle. Cerebrolysin has, by a wide margin, the largest human trial base of any nootropic-adjacent peptide, plus real approvals in many countries for stroke, traumatic brain injury, and dementia. That is the upside. The catch is that the picture is sharply split. Every positive trial and meta-analysis was funded by the maker, EVER Pharma, with company staff as co-authors, while both independent Cochrane reviews came back null or negative. The largest acute-stroke trial was neutral on its main outcome, per Heiss et al. 2012. So Cerebrolysin is not a top pick for a healthy biohacker. Its real signal, if there is one, is in acute neuro-recovery, not in sharpening an already-healthy brain.
Terminology
A few terms decide how you read this report, because Cerebrolysin lives in the gap between a large trial count and a contested verdict, and the words around that gap matter. The single most important distinction is who paid for a study, because that is where the whole controversy sits.
- Neurotrophic: Acting like the body's own nerve growth factors. Cerebrolysin is claimed to be neurotrophic, meaning it is meant to support nerve growth and survival, though that is mechanistic inference rather than proven human pharmacology.
- Biological: A medicine made from living tissue rather than synthesized from defined chemicals. Cerebrolysin is a pig-brain extract, so its exact makeup varies batch to batch.
- IV and IM: Intravenous (into a vein, by drip) and intramuscular (into a muscle, by injection). These are the only ways Cerebrolysin is given; there is no working oral form.
- Cochrane review: An independent, structured summary of all the trials on a question, widely treated as a high bar for unbiased evidence. The two Cochrane reviews of Cerebrolysin disagree with the maker's trials.
- Industry-funded: Paid for by the company that sells the product. Every positive Cerebrolysin trial was industry-funded, which is a known source of optimistic bias.
- Serious adverse event: A medical problem during a trial that is life-threatening, causes hospitalization, or similar. The independent stroke review found more non-fatal ones on the drug.
- Standardized mean difference: A way to express effect size across different scales. For Cerebrolysin, the effects cluster in the small-to-medium range.
How do you take Cerebrolysin?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 2 routes and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Intravenous infusion | Clear injectable solution in ampoules or vials, diluted and infused | 10 to 50 mL per day across a multi-week course in the studied indications | Often 5 to 10 mL per day self-run, frequently switched to IM to skip the IV setup |
| Intramuscular injection | Same injectable solution, smaller volumes given IM | Up to about 5 mL per injection for lower-volume courses | Commonly chosen over IV by self-sourcing users to avoid an infusion line |
Protocols
Acute ischemic stroke (studied) Clinical
- Dose
- 30 mL per day IV
- Frequency
- Once daily
- Duration
- 10 days
The schedule used in the CASTA trial, which was neutral on its primary endpoint. This is also the higher cumulative dose the Cochrane stroke review linked to more non-fatal serious adverse events.
Stroke motor recovery with rehab (studied) Clinical
- Dose
- 30 mL per day IV
- Frequency
- Once daily
- Duration
- 21 days, started 24 to 72 hours after stroke
The CARS rehab schedule, run alongside standardized physical rehabilitation, not as a standalone treatment.
Moderate-to-severe brain injury (studied) Clinical
- Dose
- 50 mL per day IV, then two cycles of 10 mL per day
- Frequency
- Once daily within each cycle
- Duration
- 10 days at 50 mL, then two further 10-day cycles at 10 mL
The cyclic CAPTAIN dosing for moderate-to-severe traumatic brain injury.
Dementia courses (studied) Clinical
- Dose
- About 30 mL per day IV
- Frequency
- Once daily
- Duration
- Roughly 4-week courses, repeated in cycles
Typical Alzheimer's and vascular dementia trial courses. Benefit appeared to fade between cycles, which is why repeat courses are used.
How this score is calculated →
What are the benefits of Cerebrolysin?
Upside contribution: 1.98
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.0 | 0.750 | |
| Breadth | 15% | 3.5 | 0.525 | |
| Evidence | 25% | 2.8 | 0.700 | |
| Speed | 10% | 3.0 | 0.300 | |
| Durability | 10% | 2.5 | 0.250 | |
| Bioindividuality | 15% | 3.0 | 0.450 | |
| Total | 2.975 |
Upside Rationale
Cerebrolysin's upside comes from sheer human-data volume and a broad set of real, if modest, recovery indications, not from any single transformative effect. The strongest support is the brain-injury recovery signal that reaches significance at day 30 and day 90, per Vester et al. 2021. The boundary that defines every upside dimension here is the same one: the positive results all come from trials the maker funded, and the independent reviews do not confirm them. That tension is why Evidence is held low even though the trial count is high, and it is the single most honest thing I can tell you about this compound.
Efficacy (3.0/5.0): Efficacy is moderate because the effects are real but small-to-medium and concentrated in recovery, not enhancement. Across trials the effect sizes cluster around a standardized mean difference of 0.31 to 0.40, occasionally larger in a single rehab measure, with the arm-recovery effect reaching about 0.71 when paired with physical therapy, per Muresanu et al. 2016. The Alzheimer's pooled cognitive benefit was about 0.40 at 4 weeks, per Gauthier et al. 2015. These are meaningful but modest numbers, and they describe sick brains recovering, not healthy brains improving. The figure also sits below what the raw trial count might suggest, because the strongest positive results come from maker-funded studies that the independent reviews do not back.
Breadth of Benefits (3.5/5.0): Breadth is the relative bright spot, because Cerebrolysin has actual human data across an unusually wide set of neurological indications. It has been studied in acute ischemic stroke, post-stroke motor recovery, moderate-to-severe traumatic brain injury, vascular dementia, and Alzheimer's disease, with a small-to-medium recovery effect reported across the brain-injury trials, per Muresanu et al. 2020. That is a broader human footprint than most peptides in this space can claim. The honest limit is that breadth here means many indications with a modest and contested signal in each, rather than one deep, well-confirmed effect. The wide reach is genuine; the depth in any single use is the part that stays unsettled.
Evidence Quality (2.8/5.0): Evidence is the dimension I am deliberately holding low, and it is the crux of the whole report. The raw volume is high, with thousands of trial participants across multiple multicenter trials and several meta-analyses. The problem is that every positive trial and meta-analysis was funded by the maker, EVER Pharma, with company employees co-authoring, while the two independent Cochrane reviews came back null or negative. The independent stroke review of seven trials found no benefit on death and a signal of more non-fatal serious adverse events, per Ziganshina et al. 2023, and the vascular dementia review rated all its benefit very low quality and entirely industry-funded, per Cui et al. 2019. When the independent look disagrees with the maker's look, the independent verdict has to set the ceiling, which is why Evidence sits below what trial count alone would imply.
Speed of Onset (3.0/5.0): Speed is moderate because Cerebrolysin works on a course-based timeline of days to weeks rather than a single fast dose. Neurological improvement scales moved by roughly day 14 to day 21 in the rehab trials, and the broader recovery and global measures reached significance by day 30 to day 90, per Vester et al. 2021. That is faster than a chronic supplement that takes months to show anything, but it is still a multi-week treatment course, not an acute single-dose effect. The realistic expectation is that any benefit accrues across a course, which fits the way the trials dosed it.
Durability (2.5/5.0): Durability is low-to-moderate because the benefit appears to fade once a course ends. The clearest signal comes from the Alzheimer's data, where the cognitive benefit was significant at 4 weeks but had lost significance by 6 months, per Gauthier et al. 2015. That waning is why the treatment is given in repeated cycles rather than a single course. The Cochrane reviews did not establish any durable functional benefit either. So while there is a real acute-to-subacute effect, the evidence for lasting change without re-dosing is weak, and that uncertainty is what keeps this dimension below the middle.
Bioindividuality Upside (3.0/5.0): Response varies enough by clinical context that this dimension lands at moderate. The signal is stronger in more severe presentations, with the severe-stroke subgroup and the moderate-to-severe brain-injury patients showing the clearest recovery effects, per Muresanu et al. 2020. It is weaker or absent in milder cases and has no demonstrated effect at all in healthy-cognition enhancement. Community reports also describe wide variation, with a meaningful share of users saying they felt nothing. The predictable modifier, severity of the underlying injury, lifts this above a coin flip, but it also means a healthy person is exactly the wrong candidate to expect a clear response.
What are the risks & downsides of Cerebrolysin?
Downside contribution: 1.81 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 2.5 | 0.750 | |
| Side effects | 15% | 2.6 | 0.390 | |
| Cost | 5% | 3.0 | 0.150 | |
| Effort | 5% | 4.0 | 0.200 | |
| Opportunity | 5% | 3.0 | 0.150 | |
| Dependency | 15% | 2.0 | 0.300 | |
| Reversibility | 25% | 1.8 | 0.450 | |
| Total | 2.390 | |||
| Harm subtotal × 1.4 | 2.646 | |||
| Opportunity subtotal × 1.0 | 0.500 | |||
| Combined downside | 3.146 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.806 |
Downside Rationale
Cerebrolysin's downside is dominated by practical burden and evidence uncertainty rather than acute danger. The single heaviest drag is Effort, because this is a clinic-administered IV or IM infusion given in repeated multi-week courses, not a pill. The most-exposed person is anyone trying to self-source and self-administer a biological injectable from the grey market, where sterility and counterfeit risk are real. The safety concern that does exist is mostly the independent signal of more non-fatal serious adverse events, per Ziganshina et al. 2023, plus the inherent risk of a foreign-protein product, rather than any built-in life-threatening mechanism.
Safety Risk (2.5/5.0): Safety is moderate, sitting above benign but well short of dangerous. There is no intrinsic life-threatening mechanism in humans, and fatal serious adverse events were not increased in the independent stroke review, per Ziganshina et al. 2023, so there is no built-in fatal floor here. What keeps it above benign is that Cerebrolysin is a foreign-protein biological, so rare hypersensitivity or allergic reactions are possible, and a pig-brain extract carries a category-level concern even where no transmission event has been documented. The grey-market sterility risk is real but extrinsic to the compound itself, so it belongs in the verdict and sourcing guidance rather than inflating this intrinsic score. Used as a verified pharmaceutical product under supervision, the intrinsic safety is moderate, not alarming.
Side Effect Profile (2.6/5.0): Side effects are pushed above neutral mainly by the independent harm signal. The independent Cochrane stroke review found a statistically significant increase in non-fatal serious adverse events on Cerebrolysin, larger at the common 30 mL by 10-day schedule, per Ziganshina et al. 2023. That contradicts the maker trials' comparable-to-placebo framing and is the most important everyday-risk finding in the file. On top of that, dizziness or vertigo was the most common reported side effect in dementia trials, per Plosker and Gauthier 2009, with occasional agitation, insomnia, and injection-site reactions. None of that is catastrophic, but it is more than a clean profile.
Financial Cost (3.0/5.0): Cost is moderate and recurring. Cerebrolysin is given as multi-vial infusion courses repeated in cycles, so the per-course spend is meaningful and adds up across repeat treatment, even if a single ampoule is not expensive. It runs cheaper than a chronic prescription biologic but pricier than an oral nootropic, and grey-market pricing is variable and unpredictable on top of the clinical-administration cost. The relevant framing is the total cost of a real treatment course plus the clinic time, not the sticker price of one vial.
Time/Effort Burden (4.0/5.0): Effort is the worst dimension by a clear margin, and it is the single biggest practical reason Cerebrolysin is hard to recommend casually. It is administered by intravenous infusion, or intramuscular injection for lower volumes, in multi-day courses that are often repeated as cycles, with large daily volumes that need a slow drip. The studied stroke schedule alone was 30 mL per day IV for 10 days, per Heiss et al. 2012, and the brain-injury protocol stacked a 50 mL course plus two more cycles. That is categorically harder than swallowing a pill or doing a simple under-the-skin peptide injection.
Opportunity Cost (3.0/5.0): Opportunity cost is moderate and real. The clinic time and infusion logistics of repeated courses are a genuine drain compared with lower-effort alternatives that target similar goals. For a healthy person chasing cognitive enhancement, the time and money would almost certainly do more elsewhere, since Cerebrolysin has no healthy-population enhancement data and its recovery signal does not transfer to a well brain. It is not a severe opportunity cost the way a daily multi-hour protocol would be, but the infusion burden plus the contested evidence means the expected payoff per hour invested is low for most people.
Dependency/Withdrawal (2.0/5.0): Dependency risk is low. Cerebrolysin has no addictive or craving profile, and there is no documented withdrawal syndrome when a course ends. The only mild caveat is functional: because the benefit appears to fade between courses, people re-dose in cycles to sustain any effect, which is functional reliance rather than addiction. Nothing in the trial record describes rebound or escalating-dose behavior, so this dimension stays well below the middle.
Reversibility (1.8/5.0): Reversibility is excellent, one of the genuine strengths here. The effects clear after a course ends, with the cognitive benefit in dementia fading by 6 months, per Gauthier et al. 2015, and stopping carries no documented withdrawal or lasting change. There is no taper requirement and no permanent alteration to undo. If a course goes badly or simply does nothing, stopping returns things to where they started, which is exactly what you want from a reversibility standpoint.
Is Cerebrolysin worth it?
Cerebrolysin lands at Neutral because it pairs the largest human trial base of any nootropic-adjacent peptide with an evidence story that independent reviewers do not confirm, plus a heavy infusion burden. If you are investigating acute neuro-recovery, severe stroke or moderate-to-severe brain injury, and you can access supervised clinic infusions and verified product, it is a reasonable thing to research with a clinician. If you are a healthy person hoping for a cognitive edge, the data is simply not there, and the effort and sourcing risk are high. The two real-world frictions that decide most cases are the IV or IM infusion burden and the grey-market sterility risk of an injectable biological.
✅ Best for: People investigating recovery from severe ischemic stroke, where the severe subgroup showed the clearest signal, who are working with a clinician. People dealing with moderate-to-severe traumatic brain injury who can access supervised infusion courses, since that is one of its better-supported uses, per Muresanu et al. 2020. Patients in countries where it is approved and supplied through a real pharmacy rather than imported. Anyone who can verify they have genuine EVER Pharma product and a clinical setting for sterile administration. Researchers and informed users who understand the evidence is split and want the recovery context, not an enhancement promise.
❌ Avoid if: You are a healthy person seeking cognitive enhancement, since there is no trial showing benefit in a well brain and the burden is high. You have a known allergy or hypersensitivity to biological or animal-derived products, given the foreign-protein anaphylaxis risk. You have active or suspected cancer, where a growth-factor-mimicking biological is unwise without specialist guidance. You cannot source verified product and would be relying on grey-market vials, because sterility, cold-chain, and counterfeit risk for an injectable can exceed the compound's own risk. You want a low-effort routine, because repeated multi-week clinic infusions are the opposite of that.
What is Cerebrolysin best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| ○ Cognition / Focus Primary | 4.2 | Cognition is the most-claimed and best-studied use, but the human signal is real and contested at once, so it scores moderate rather than high. In mild-to-moderate Alzheimer's, pooled trials showed a cognitive benefit at 4 weeks (a standardized mean difference of about 0.40) that lost significance by 6 months, per Gauthier et al. 2015. The honest caveat: that meta-analysis was authored by people affiliated with the maker, EVER Pharma. There is no trial showing cognitive enhancement in healthy people, so this is recovery-context cognition, not a study-aid effect for a well brain. |
| ○ Memory Primary | 4.0 | Memory tracks the same dementia data as the broader cognition picture, which is why it earns a moderate score with a real caveat rather than a high one. The pooled Alzheimer's cognitive measures, which include memory-loaded scales, improved early then faded by 6 months, per Gauthier et al. 2015, and the vascular dementia pooled cognition effect was rated very low quality, per Cui et al. 2019. Both signals come from maker-funded trials, and the independent review verdict caps how much weight memory can carry here. No healthy-population memory trial exists. |
| ○ Neuroprotection Primary | 4.5 | Neuroprotection is the central claim and the indication set with the most human data, so it scores in the moderate-to-high band while staying honest about the split. Manufacturer-funded acute-stroke and brain-injury trials report small-to-medium recovery effects, with the brain-injury pooled analysis showing significant benefit at day 30 and day 90, per Vester et al. 2021. The crucial caveat: the independent Cochrane stroke review found no benefit on death and a signal of more non-fatal serious adverse events, per Ziganshina et al. 2023. So the neuroprotection story is genuinely the strongest one Cerebrolysin has, but it is far from settled. |
| ○ Traumatic Brain Injury Primary | 4.3 | Traumatic brain injury is one of Cerebrolysin's better-supported uses, with a small-to-medium recovery effect in moderate-to-severe injury, which is why it scores moderate-to-high rather than higher. The single-center CAPTAIN II trial in patients with Glasgow Coma Scale scores of 7 to 12 showed a significant multivariate benefit at day 90, per Muresanu et al. 2020, and the pooled CAPTAIN analysis confirmed significant effects at day 30 and day 90, per Vester et al. 2021. The caveat that holds the score below high: these are maker-funded trials with company staff as co-authors, and there is no independent confirmation. |
Frequently Asked Questions
What is Cerebrolysin and what is it made from?
Cerebrolysin is a porcine brain-derived mixture of low-molecular-weight peptides and free amino acids, not a single defined molecule, per Ziganshina et al. 2023. It is made by EVER Pharma in Austria and marketed as neurotrophic, meaning it is meant to act like the body's own nerve growth factors. Because it is a biological extract from pig brain tissue, its exact composition varies batch to batch, and it is given only by injection.
How is Cerebrolysin given, and can you take it as a pill?
Cerebrolysin is given only by intravenous infusion or intramuscular injection, never as a pill, because the peptide fraction would be digested. In the trials it ran as multi-week courses, for example 30 mL per day IV for 10 days in stroke, per Heiss et al. 2012. Larger daily volumes need a slow IV drip in a clinic; self-sourcing users often switch to lower-volume IM to skip the line. Courses are frequently repeated in cycles, which makes it a high-effort treatment.
Does Cerebrolysin actually work, or is the evidence biased?
The evidence is split, which is the whole story. Every positive trial and meta-analysis was funded by the maker with company staff co-authoring, while the two independent Cochrane reviews are null or negative, per Cui et al. 2019. The independent stroke review found no benefit on death and more non-fatal serious adverse events on the drug, per Ziganshina et al. 2023. So there is a large trial base, but the most trustworthy independent look does not confirm the maker's results.
What does the stroke evidence on Cerebrolysin show?
The stroke picture is mixed. The largest acute-stroke trial, CASTA, with 1,070 patients, was neutral on its primary endpoint, per Heiss et al. 2012. A separate rehab trial reported a large arm-recovery effect when paired with physical therapy, per Muresanu et al. 2016, but that was maker-funded. The independent Cochrane review pooled seven trials and found no death benefit plus more non-fatal serious adverse events. So any stroke use is contested, not settled.
What does the brain injury and dementia evidence show?
In moderate-to-severe brain injury, pooled maker-funded trials showed a small-to-medium recovery benefit at day 30 and day 90, per Vester et al. 2021. In dementia, an Alzheimer's meta-analysis showed cognitive gains at 4 weeks that faded by 6 months, per Gauthier et al. 2015. The independent vascular dementia Cochrane review rated all of its benefit very low quality and entirely industry-funded. The brain injury and dementia signals are real but modest and not independently confirmed.
Is Cerebrolysin safe, and what are the side effects?
Cerebrolysin is generally tolerable, but the independent Cochrane stroke review found more non-fatal serious adverse events on the drug, per Ziganshina et al. 2023, which contradicts the maker trials' comparable-to-placebo framing. The most common everyday side effect in dementia trials was dizziness or vertigo, per Plosker and Gauthier 2009. Because it is a foreign-protein biological, rare hypersensitivity or allergic reactions are possible. Fatal serious adverse events were not increased, so there is no built-in life-threatening signal.
How do you source Cerebrolysin safely, and is it legal in the US?
Cerebrolysin is not FDA-approved in the US, so there is no legal pharmacy supply and access is grey-market import, per Ziganshina et al. 2023. For an injectable biological, that means real sterility, cold-chain, and counterfeit risk that goes well beyond a small-molecule supplement. If someone pursues it anyway, the only defensible path is verified EVER Pharma product and a clinician supervising sterile administration, not a random vendor vial.
Cerebrolysin versus oral nootropics: which makes more sense?
For a healthy person chasing cognitive enhancement, oral options usually make more practical sense, because Cerebrolysin needs clinic infusions and has no healthy-population enhancement trial. Its real signal is in acute neuro-recovery, not study-aid effects. If you want lower-effort routes worth investigating, the Semax report covers an intranasal peptide and the Lion's Mane report covers an oral mushroom. Cerebrolysin trades a much heavier burden for a contested, recovery-focused benefit.
What could change Cerebrolysin's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The fastest way Cerebrolysin moves up is a large independent, non-industry-funded trial that confirms a real recovery benefit, and the fastest way it moves down is a strengthened independent harm signal or a clear failed replication. Because the current score is held back specifically by the gap between maker-funded positives and null independent reviews, the dimension most sensitive to new data is Evidence, with Efficacy close behind. Confirmation or refutation from an independent group would move this score more than another maker-funded trial ever could.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| A large independent, non-industry trial confirms a real recovery benefit | Evidence 2.8 to 3.8, Efficacy 3.0 to 3.5 | 5.7 / 10 ⚖️ Neutral |
| An independent meta-analysis confirms the brain-injury recovery effect | Evidence 2.8 to 3.3, Breadth 3.5 to 3.8 | 5.4 / 10 ⚖️ Neutral |
| A practical lower-volume or shorter-course protocol is validated | Effort 4.0 to 3.0 | 5.3 / 10 ⚖️ Neutral |
| A stronger independent serious-adverse-event signal emerges | Side Effects 2.6 to 3.6, Safety 2.5 to 3.2 | 4.7 / 10 ⚖️ Neutral |
| A large independent trial fails to beat placebo on a marketed use | Efficacy 3.0 to 2.2, Evidence 2.8 to 2.2 | 4.8 / 10 ⚖️ Neutral |
| Repeated counterfeit or contamination findings dominate the grey market | Safety 2.5 to 3.2, Bioindividuality 3.0 to 2.5 | 4.8 / 10 ⚖️ Neutral |
The largest acute ischemic stroke trial of Cerebrolysin, with 1,070 patients on a 30 mL per day schedule, showed no significant difference from placebo on its primary global outcome at 90 days. The positive results that exist sit in maker-funded rehabilitation and brain-injury trials, not in this neutral flagship. Heiss et al. 2012, Stroke (CASTA)
Pooling seven stroke trials with 1,773 participants, the independent review found no beneficial effect on preventing death and a signal of more non-fatal serious adverse events on Cerebrolysin, while noting the manufacturer had supported three of the studies. That independent verdict is why the evidence dimension is held low. Ziganshina et al. 2023, Cochrane Database of Systematic Reviews
For a lower-effort peptide with a cleaner repair-axis profile and simple under-the-skin dosing, the BPC-157 report covers a compound that scores higher on practicality, though its human evidence is thinner than Cerebrolysin's contested trial base.
This is research and educational information, not medical advice. Cerebrolysin is not FDA-approved in the US, and nothing here is a recommendation to obtain, import, or self-administer it. Talk with a qualified clinician before acting on anything in this report.
BioHarmony Engine v1.0
Key Evidence Sources
- Heiss et al. 2012, Stroke: CASTA, the largest acute ischemic stroke trial of Cerebrolysin (n=1,070), was neutral on its primary global outcome at 90 days.. 2012 RCT, n=1,070, neutral primary endpoint; 30 mL per day IV for 10 days within 12 hours of onset.
- Ziganshina et al. 2023, Cochrane Database of Systematic Reviews: independent review of seven stroke RCTs (1,773 participants) found no benefit on death and more non-fatal serious adverse events on Cerebrolysin.. 2023 Cochrane review, 7 trials, 1,773 participants; death RR 0.96, non-fatal serious adverse events increased; EVER Pharma sponsor supported three of the studies (COI noted).
- Cui et al. 2019, Cochrane Database of Systematic Reviews: independent vascular dementia review of six RCTs (597 participants) rated cognitive benefit very low quality and all studies industry-funded.. 2019 Cochrane review, 6 trials, 597 participants; cognition standardized mean difference about 0.36, very low quality; all funded by industry, EVER Pharma sponsor context.
- Muresanu et al. 2016, Stroke: the CARS rehabilitation trial reported a large arm-recovery effect at day 90 when Cerebrolysin was paired with standardized physical therapy.. 2016 RCT, 30 mL per day IV for 21 days plus rehab; arm-recovery effect estimator about 0.71; EVER Pharma staff among authors (industry sponsor COI).
- Guekht et al. 2017, Neurological Sciences: pooled CARS rehab analysis (442 patients) showed early neurological and arm-recovery benefit, with full disclosure of EVER Pharma relationships.. 2017 meta-analysis, 442 patients; arm-recovery estimator about 0.62, number-needed-to-treat about 7 for early benefit; extensive EVER Pharma sponsor and COI disclosure.
- Muresanu et al. 2020, Neurological Sciences: the single-center CAPTAIN II trial (n=142) in moderate-to-severe brain injury showed a significant multivariate recovery benefit at day 90.. 2020 single-center trial, n=142, Glasgow Coma Scale 7 to 12; small-to-medium effect significant at day 90; safety comparable to placebo; EVER Pharma sponsor with company-staff COI.
- Vester et al. 2021, Neurological Sciences: pooled CAPTAIN brain-injury analysis (n=185) showed small-to-medium recovery effects significant at day 30 and day 90.. 2021 meta-analysis, n=185; day-30 standardized mean difference about 0.31, day-90 about 0.34; first author is the EVER Pharma sponsor-affiliated biometrician (COI).
- Gauthier et al. 2015, Dementia and Geriatric Cognitive Disorders: Alzheimer's meta-analysis (six RCTs) showed cognitive benefit at 4 weeks that lost significance by 6 months.. 2015 meta-analysis, 6 RCTs; cognition standardized mean difference about 0.40 at 4 weeks, non-significant by 6 months; EVER Pharma sponsor-affiliated authors (COI).
- Plosker and Gauthier 2009, Drugs and Aging: narrative dementia review describing the neurotrophic-like mechanism and naming dizziness or vertigo as the most common adverse event.. 2009 narrative review of dementia trials; mechanism framing and tolerability summary; industry-adjacent context.
- Al-Kuraishy et al. 2025, Neuroscience: independent mechanistic review on the possible role of cerebrolysin in the management of vascular dementia, proposing blood-brain-barrier crossing and neurotrophic-like induction of neurogenesis, neuroplasticity, and neuroprotection.. 2025 mechanistic review of cerebrolysin in vascular dementia management; proposed targets include neuroinflammation and blood-brain-barrier injury; independent author disclosures.
- Hong et al. 2009, International Journal of Stroke: the CASTA design and protocol paper detailing the 30 mL per day IV stroke schedule used in the trial.. 2009 trial design paper; documents the 30 mL per day IV for 10 days schedule; EVER Pharma sponsor-affiliated author present (COI).
What does the evidence say about Cerebrolysin?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
Citations: Heiss 2012, Ziganshina 2023, Cui 2019, Vester 2021, Gauthier 2015
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Cbc Pre | Expected Watch
- CRP During | Expected Watch
Pulse Dimensions to Watch
- Drive During | Expected Up | Primary
- Calm During | Expected Watch | Secondary
- Energy During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Mental clarity, focus, and verbal fluency during the course Scale 1-5 | During | Expected Up
- Injection or infusion site reaction, warmth, swelling, or flushing Scale 1-5 | During | Expected Watch
- Restlessness, agitation, or trouble sleeping on higher daily volumes Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Any sign of an allergic or hypersensitivity reaction to the biological (hives, swelling, wheezing, throat tightness): stop and seek emergency care, since it is a foreign-protein product.
- New seizure, confusion, or a marked worsening of neurological symptoms during a course: stop and consult a clinician.
- Fever, spreading redness, or pus at an injection or infusion site (possible contamination from grey-market product): stop and seek care.
- Any active or suspected cancer: do not use a growth-factor-mimicking biological without specialist guidance.
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.975 − 1.806 = 0.169
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.169 / 5) × 5 = 5.2 / 10
